US Capitol Capsule: Timing or economics? US vulnerable after flu vaccine mismatch
This article was originally published in Scrip
Executive Summary
When US government officials this past summer realized there may potentially be a problem with the effectiveness of the flu vaccine about to be shipped to thousands of doctor offices, health clinics and pharmacies, a question that may be asked by lawmakers at a 3 February Capitol Hill hearing is why manufacturers didn't shift gears and quickly make a vaccine that was better matched to what would become the predominantly circulating A (H3N2) virus.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.